Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Dual-phase PET-CT to differentiate [¹⁸F]fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer|
|Other Titles:||Dual-phase PET-CT to differentiate [(18)F]fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer|
van Moorselaar, R.
van den Eertwegh, A.
|Citation:||PLoS One, 2012; 7(10):e48430-e48430|
|Daniela E. Oprea-Lager, Andrew D. Vincent, Reindert J. A. van Moorselaar, Winald R. Gerritsen, Alfons J. M. van den Eertwegh, Jonas Eriksson, Ronald Boellaard, Otto S. Hoekstra|
|Abstract:||PURPOSE: To investigate whether time-trends of enhanced [(18)F]Fluoromethylcholine ([(18)F]FCH) in lymph nodes (LN) of prostate cancer (PCa) patients can help to discriminate reactive from malignant ones, and whether single time point standardized uptake value (SUV) measurements also suffice. PROCEDURES: 25 PCa patients with inguinal (presumed benign) and enlarged pelvic LN (presumed malignant) showing enhanced [(18)F]FCH uptake at dual-phase PET-CT were analyzed. Associations between LN status (benign versus malignant) and SUV(max) and SUV(meanA50), determined at 2 min (early) and 30 min (late) post injection, were assessed. We considered two time-trends of [(18)F]FCH uptake: type A (SUV early > SUV late) and type B (SUV late ≥ SUV early). Histopathology and/or follow-up were used to confirm the assumption that LN with type A pattern are benign, and LN with type B pattern malignant. RESULTS: Analysis of 54 nodes showed that LN status, time-trends, and 'late' (30 min p.i.) SUV(max) and SUV(meanA50) parameters were strongly associated (P<0.0001). SUV(max) relative difference was the best LN status predictor. All but one inguinal LN showed a decreasing [(18)F]FCH uptake over time (pattern A), while 95% of the pelvic nodes presented a stable or increasing uptake (pattern B) type. CONCLUSIONS: Time-trends of enhanced [(18)F]FCH uptake can help to characterize lymph nodes in prostate cancer patients. Single time-point SUV measurements, 30 min p.i., may be a reasonable alternative for predicting benign versus malignant status of lymph nodes, but this remains to be validated in non-enlarged pelvic lymph nodes.|
|Rights:||2012 Oprea-Lager et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Appears in Collections:||Aurora harvest 4|
Media Studies publications
Files in This Item:
|hdl_121326.pdf||Published version||458.85 kB||Adobe PDF||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.